Thus, although guidelines give attention to treatment of CKD- bone and mineral disease, and although treatment targets are well defined, physicians are insufficiently aware of the importance of adequate treatment of hyperparathyroidism: our data point to therapeutic inertia towards the PTH treatment target. The gene discussed is PTH; the disease is hyperparathyroidism.